Steroidal anti-inflammatory drugs, nonsteroidal anti inflammatory drugs and immunomodulators have been used in the treatment of rheumatoid arthritis (RA). However, at present, there is no drug that completely cures this disease. RA is a chronic progressive inflamma tory disease, and it has been suggested that abnormalities in immunity are involved in its etiology. Thus, treatment with immunosuppressants may be useful in treating this disease.
Mizoribine (MZR), an imidazole nucleoside isolated from the culture filtrate of Eupenicillium brefeldianum (1), suppresses both the humoral and cellular immune responses (2, 3). MZR competitively inhibits inosine 5' monophosphate (IMP) dehydrogenase in the purine metabolism pathway in mouse lymphoma L5178Y cells (4). This inhibition results in a decrease in intracellular guanosine 5'-monophosphate (GMP) levels and in the suppression of cell proliferation. At present, MZR is used to treat RA (5), to suppress rejection in renal transplan tation (6-8) and to treat lupus nephritis (9). There are reports that MZR suppresses arthritis in rats with ad juvant-induced arthritis (10 12), in rats with collagen-in duced arthritis (11) and in MRL/Mp-lpr/lpr mice (13). However, the suppressive mechanism of MZR on arthritis is not clear. Collagen-induced arthritis seems to be the experimental model that is most similar to human RA.
Several previous reports suggest that both humoral and cellular immunities to type II collagen are related to the development of collagen-induced arthritis (14, 15). In this study, we investigated the suppressive effect of MZR on collagen-induced arthritis in mice, in comparison with the effect of a steroidal anti-inflammatory drug and im munomodulators. We also studied the mechanism under lying the action of MZR in this model.
MATERIALS AND METHODS

Animals
Male DBA/ 1 J mice were obtained from Charles River Japan, Inc. (Kanagawa). Mice were allowed 2 weeks to adapt to their environment in a specific pathogen-free room and were 8-weeks-old at the beginning of the ex periment. Standard laboratory food and water were available to the mice ad libitum.
Drugs
The drugs used in this experiment were MZR (Asahi Chemical Industry, Osaka), prednisolone (Shionogi & Co., Osaka), bucillamine (Santen Pharmaceutical, Osaka) and D-penicillamine (Tokyo Chemical Industry, Tokyo). The drugs were dissolved in distilled water or 0.5% sodium carboxymethylcellulose (CMC-Na; Wako Pure Chemical Industries, Osaka).
Induction of arthritis
The mice were divided into 5 or 6 groups, each with 10 animals per group. Three mg/ml of bovine type II colla gen solution (Cosmo Bio, Tokyo) was emulsified with an equal volume of complete Freund adjuvant (CFA; Difco Laboratories, Detroit, MI, USA) in a Waring blender. The emulsion, containing 200 pg of collagen, was injected intradermally (i.d.) into the back of each mouse. After 21 days, the same dose of collagen emulsion was injected i.d. at the base of the tail. Drugs were administered orally 5 days a week for 12 weeks beginning on the day after the primary immunization.
Evaluation of arthritis
The presence of arthritis was determined by examining each of the four paws and scoring on a scale of 0-4, as follows: 0, no edema; 1, edema only in the toes; 2, slight edema; 3, severe edema; 4, severe edema and ankylosis.
Each mouse was scored once a week by visual examina tion continuing through 12 weeks after immunization.
The arthritis score for each animal was calculated as the total of the scores for all four limbs. Therefore, the maxi mum score was 16. If the total arthritis score was more than 1, we regarded the mouse as having developed arthritis. The incidence of arthritis was also determined.
Radiological examination
At the end of the experimental period, both hind limbs were cut off at the middle of the femoral diaphysis. Soft X-ray photographs of the hind limbs were taken with an X-ray unit (Type SRO-M50; Sofron, Tokyo). Bone damage in the hind limbs was scored on a scale of 0-4 according to the scoring method reported for collagen induced arthritis in rats (12).
Anti-type II collagen antibody titer Sera were routinely collected by retroorbital bleeding, using a capillary tube, 8 and 12 weeks after immuniza tion. Serum anti-type II collagen antibody levels were measured using the enzyme-linked immunosorbent assay (ELISA) technique.
Immunoplates (Nunc, Roskilde, Denmark) were coated with 50,ul of bovine type II colla gen at a concentration of 4 pg/ml and incubated over night at 41C. The plates were washed three times with phosphate-buffered saline containing 0.05% Tween 20 (PBS-Tween) and blocked with PBS containing 1010 bo vine serum albumin (PBS-101oBSA). After 1-hr incuba tion at room temperature, the plates were washed three times with PBS-Tween. Fifty-microliter aliquots of serum samples, diluted 1:6400 with PBS I01oBSA, were added to the wells. After a 1-hr incubation at room temperature, the plates were washed four times with PBS-Tween. Fifty microliters of peroxidase-conjugated goat anti mouse IgG(r), 1:2000 dilution (Kirkegaard & Perry Laboratories Inc., Gaithersburg, MD, USA), was added. After an additional 1-hr incubation at room temperature, the plates were washed four times with PBS-Tween. Fifty microliters of 2,2'-azino-bis(3-ethylbenzthiazoline 6-sulfonic acid) (ABTS, Wako Pure Chemical Industries) solution was added as substrate. After a 30-min incuba tion at 37 C , the reaction was stopped by adding 50 pl of 5 % oxalic acid. The reaction product was measured by determining the absorbance at 415-492 nm with a micro plate photometer (MTP-22; Corona Electric, Ibaraki).
Delayed-type hypersensitivity (DTH) response
The DTH response to type II collagen was determined 12 weeks after immunization. A 25-pl aliquot of 0.4 mg/ml collagen solution (containing 0.2 M NaCI and 0.05 M Tris-HCl, pH 7.5) was injected i.d. into the skin of the left ear, and an equal volume of the buffer solution was injected into the skin of the right ear. After 24 and 48 hr, the thickness of both ears was measured with an Upright Dial Thickness Gauge (Ozaki Seisakusyo, Tokyo). The difference in thickness between the collagen and buffer injected ears was regarded as the index of DTH response.
Lymphocyte subpopulations of splenocytes
At the end of the experimental period, the spleens were removed from 4 mice in each group. Splenocytes were labeled with anti-mouse Thyl.2, B220, L3T4 and Lyt-2 monoclonal antibodies (Becton Dickinson, San Jose, CA, USA). Lymphocyte subpopulations were measured by FACScan (Becton Dickinson).
Statistical analyses
Statistical analyses were done with Student's t-test.
Comparisons between the arthritic control and other groups were done. The results were considered to be sig nificantly different when P values were less than 0.05.
RESULTS
Arthritis score
The dose-dependency of the suppressive effect of MZR on collagen-induced arthritis in mice was examined. DBA/ 1 J mice were immunized on days 0 and 21 with 200 pg of type II collagen in CFA. These immunizations resulted in the development of arthritis in all animals. The mice developed arthritis after receiving the booster injec tion, and the arthritis score of the control group was 8.4, 12 weeks after the primary immunization (Fig. 1) . The mice were treated with various doses of MZR (10, 20 and 50 mg/kg) for 12 weeks beginning on the day after the dence of arthritis in the control group was 90%, 5 weeks after immunization. Treatment with MZR, at doses of 20 and 50 mg/kg, reduced this incidence to 70% and 50%, respectively, in the same period. Furthermore, 7 weeks after immunization, 100% of the animals in the control group had developed arthritis, whereas, in the mice treat ed with MZR at doses of 10 and 20 mg/kg, a 100% inci dence of arthritis was seen 8 and 9 weeks, respectively, after immunization (data not shown). Therefore, it ap peared that MZR also delayed the development of arthri tis. Only 10% of the mice treated with prednisolone de veloped arthritis during this experimental period. The suppressive effect of MZR on collagen-induced arthritis was compared with that of various other drugs, i.e., a steroidal anti-inflammatory drug and immuno modulators (Fig. 2) . The arthritis score of the control group was 10.7, 12 weeks after immunization.
The scores of mice treated with MZR at doses of 50 and 100 mg/kg were 5.2 and 2.7, respectively, in the same period. Prednisolone markedly reduced the arthritis score to 0.4, even at a dose of 1 mg/kg. On the other hand, bucilla mine, at a dose of 50 mg/kg, slightly but not significantly reduced the score, and D-penicillamine, at the same dose, did not reduce the score. The incidence of arthritis in the control group was 100%, 9 weeks after immunization, whereas, in the group treated with MZR, at a dose of 100 mg/kg, the incidence of arthritis was 80%, at the end of the experimental period. Prednisolone reduced the inci dence of arthritis to 40%. Bucillamine and D-penicilla mine did not delay the development of arthritis (data not shown).
Radiological examination
The bone damage scores of the hind limbs are shown in 
Lymphocyte subpopulations of splenocytes
At the end of the experimental period, the spleens were removed, and the lymphocyte subpopulations of spleno cytes, i.e., Thy1.2+, B220+, L3T4+ and Lyt-2+, were ana lyzed. The ratios of L3T4+/Lyt-2+ and B220+/Thy1.2+
are shown in Table 4 . An imbalance was observed in the ratio between L3T4+ and Lyt-2+ cells in the arthritic mice. MZR restored the increased L3T4+/Lyt-2+ ratio to the level found in normal mice. In the mice treated with prednisolone, the elevated L3T4+/Lyt-2+ ratio decreased with significant difference from arthritic con MZR reduced the arthritis score in a dose-dependent fashion, showing significant reduction even at a dose of 10 mg/kg. Furthermore, MZR, at doses of more than 20 mg/kg, significantly suppressed bone damage in the hind limbs. Successive administration of MZR at a dose of 100 mg/kg markedly reduced the arthritis score and sup pressed the bone damage, but this dose of MZR did not affect body weight gain (data not shown). It has also been reported that MZR suppressed bone damage in the hind limbs in rats with adjuvant-induced arthritis (12). Thus, it has been demonstrated that MZR suppresses not only inflammation but also the bone damage in arthritis models.
It was previously reported that the immunosuppressant cyclosporin A had both suppressive and therapeutic effects on mice with collagen-induced arthritis (16, 17). We also found that cyclosporin A, at doses of 25 and 50 mg/kg, significantly reduced the arthritis score and sup pressed the bone damage in the hind limbs in a dose dependent fashion (data not shown), thus demonstrating that immunosuppressants are effective in reducing both inflammation and bone damage in arthritis.
The suppressive effect of the steroidal anti-inflamma tory drug prednisolone on collagen-induced arthritis in mice has already been reported (18, 19) . Paramethasone (20) and dexamethasone (21), two other steroidal anti inflammatory drugs, have also been reported to markedly suppress arthritis. In this study, prednisolone markedly suppressed the bone damage in the hind limbs and greatly reduced the arthritis score.
The immunomodulator, bucillamine, however, caused only a slight reduction of the arthritis score at a dose of 50 mg/kg, and D-penicillamine had virtually no effect at this dose. It has been reported that the immunomodulators, D-penicillamine (18-20) and lobenzalit (21), did not sup press arthritis in mice having collagen-induced arthritis. Immunomodulators, in general, are considered to be in effective in the treatment of this type of arthritis, and our results confirm this.
We also examined the effect of drugs on various im munological parameters in mice with collagen-induced arthritis. MZR, at a dose of 100 mg/kg, only slightly decreased anti-type II collagen antibody levels, but at doses of more than 50 mg/kg, it significantly suppressed the DTH response in a dose-dependent fashion. As MZR did not suppress carrageenin-induced paw edema in mice, even at a dose of 100 mg/kg (data not shown), the sup pression of the DTH response by MZR seems not to depend on anti-inflammatory action. It was shown that levels of both cellular and humoral immunity to type II collagen rose at the time arthritis appeared (22). It is suggested that cellular immunity to type II collagen is required, in addition to humoral immunity, for the con tinued development of collagen-induced arthritis (23, 24). It has been reported that MZR suppresses both cellular immunity (2, 25) and humoral immunity (3). However, MZR showed only slight suppression of antibody levels and intense suppression of DTH response in mice with collagen-induced arthritis. It seems, therefore, that MZR suppresses arthritis in these animals because of its effect on cellular immunity rather than humoral immunity.
It was reported that a significant decrease in the ratio between T cells and B cells and an increase in the ratio between L3T4+ cells and Lyt-2+ cells were observed in splenocytes from mice with collagen-induced arthritis (26). The imbalance of the lymphocyte subpopulations is suspected to be one of the causes of arthritis. We also observed the increase in the L3T4+/Lyt-2+ ratio in the arthritic mice. MZR restored the increased L3T4+/Lyt 2+ ratio to the level seen in normal mice. This restoration may be one reason for the effect of MZR on the cellular immune system. Prednisolone suppressed both anti-type II collagen an tibody levels and the DTH response in a dose-dependent fashion and reduced the elevated L3T4+/Lyt-2+ ratio to less than that of normal mice. This suggests that pred nisolone suppresses arthritis because of its ability to re store normal immune function, in addition to its well known anti-inflammatory effect. The immunomodula tors, bucillamine and D-penicillamine, did not suppress the arthritis and they had no effect on either anti-type II collagen antibody levels or the DTH response.
In conclusion, it was shown that MZR suppressed col lagen-induced arthritis in mice and reduced the degree of bone damage. Our studies suggest that the inhibitory effect of MZR is based on its suppression of cellular im munity.
The results of these studies in experimental animals provide a theoretical basis for the clinical use of MZR in rheumatoid arthritis.
